6533b856fe1ef96bd12b36d3
RESEARCH PRODUCT
Cardiovascular risk in patients without known cardiovascular disease.
Roberto G CarboneM. F. AlgahimS. RizzoA. MonseliseR. A. DartG. H. AlmassiD. D. Guttermansubject
Health Knowledge Attitudes PracticeRisk FactorModels TheoreticalCoronary heart diseaseMyocardial infarctionPatient Education as TopicCardiovascular DiseasesRisk FactorsCardiovascular DiseasePractice Guidelines as TopicBorderline risk factorHumansC Reactive ProteinCardiovascular multiple risk factorHumandescription
Understanding the risks of atherosclerotic cardiovascular disease (CVD) allows for better patient education and management. Multiple risk models have been validated in large patient populations and provide insights into the risks associated with CVD. When assessing such risks, we suggest using a model that predicts myocardial infarction, cardiovascular death, and/or cerebrovascular events. In this review, we analyze several risk models and stratify the risks associated with CVD. We suggest that appropriate profiling of patients at-risk of CVD will lead to better physician recognition and treatment of modifiable risk factors, appropriate application of ATP III treatment for hyperlipidemia, and achieving optimal blood pressure control. Understanding the risks of atherosclerotic cardiovascular disease (CVD) allows for better patient education and management. Multiple risk models have been validated in large patient populations and provide insights into the risks associated with CVD. When assessing such risks, we suggest using a model that predicts myocardial infarction, cardiovascular death, and/or cerebrovascular events. In this review, we analyze several risk models and stratify the risks associated with CVD. We suggest that appropriate profiling of patients at-risk of CVD will lead to better physician recognition and treatment of modifiable risk factors, appropriate application of ATP III treatment for hyperlipidemia, and achieving optimal blood pressure control.
year | journal | country | edition | language |
---|---|---|---|---|
2014-02-25 | European review for medical and pharmacological sciences |